Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the bodyâs own machinery â the T-cell â to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patientâs own T-cells to express our SPEAR TCRs to target and potentially destroy tumors. Source
No articles found.
Based in South San Francisco, we are a clinical-stage biotechnology company commit...
Based in South San Francisco, we are a clinical...
NanoVibronix Inc. is a medical device company that is focused on creating medical ...
NanoVibronix Inc. is a medical device company t...
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a rapidly growing comme...
BioDelivery Sciences International, Inc. (NASDA...
Terumo Corporation is a manufacturer and supplier of pharmaceuticals and medical t...
Terumo Corporation is a manufacturer and suppli...
Optinose is a specialty pharmaceutical company focused on creating and bringing to...
Optinose is a specialty pharmaceutical company ...
PLx Pharma Inc. (Nasdaq: PLXP), is a late-stage specialty pharmaceutical company i...
PLx Pharma Inc. (Nasdaq: PLXP), is a late-stage...
Neon Therapeutics is a clinical-stage immuno-oncology company leading in the field...
Neon Therapeutics is a clinical-stage immuno-on...
Join the National Investor Network and get the latest information with your interests in mind.